Paper 16 - ACTIVITY OF ADAPT-001 WITH A CHECKPOINT INHIBITOR IN ANGIOSARCOMA PATIENTS REFRACTORY TO CHECKPOINT INHIBITION

Co-Author(s)

• 

  Vinod Ravi, MD

  Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• 

  Anthony P. Conley, MD

  Associate Professor
  University of Texas MD Anderson Cancer Center
  Houston, Texas, United States
• BO

  Bryan Oronsky, MD, Ph.D.

  Epicentrx
  La Jolla, California, United States
• AS

  Ana B. Sanchez, Ph.D.

  Epicentrx
  La Jolla, California, United States
• FH

  Farah Hedjran, MS

  Epicentrx
  La Jolla, California, United States
• SC

  Scott Caroen, MS

  Epicentrx
  La Jolla, California, United States
• MS

  Meaghan Stirn, MBA

  Epicentrx
  La Jolla, California, United States
• 

  Christopher Larson, MD, Ph.D.

  Vice President of Viral Therapy. Sarcoma medical oncologist.
  Epicentrx
  La Jolla, California, United States

Author(s)

• 

  Tony Reid, MD, PH.D.

  Professor, Hematology/Oncology.
  UC San Diego
  La Jolla, California, United States

  Slides